Lexaria Bioscience Corp. (NASDAQ: LEXX) Steadily Achieving Its Operational and Business Plan Objectives

August 2, 2021 12:23:57
  • Lexaria just completed dosing for its second human clinical study, HYPER-H21-2
  • The study sought to understand the human response to Lexaria’s DehydraTECH 2.0-enabled CBD
  • The company also announced that its DehydraTECH-enabled consumer products are available for purchase in over 7,000 stores across the United States
  • Lexaria also expanded its intellectual property portfolio with the allowance of its second patent in Japan
  • It also received US$3,817,643 from warrant exercises, proceeds from which will be used to advance the company’s research and development program and for its general corporate purposes
Lexaria Bioscience (NASDAQ: LEXX) has been making incredible strides in 2021 as it works towards achieving its business plan objectives. At the beginning of the year, the company set out to conduct three human clinical studies, two of which are underway at the time of this article.  Its most recent human clinical study, HYPER-H21-2, dosing was completed in July 2021 and was designed to understand better the human response to Lexaria’s DehydraTECH 2.0-enabled CBD (https://cnw.fm/Tzr2W). The company projects that preliminary results would be available for reporting either in September or earlier. This second human clinical trial involved 16 human volunteers who previously dealt with hypertension or were mildly hypertensive at the time of the study. Each of the 16 participants received three different doses of 150 mg each of DehydraTECH(TM) 2.0-enabled CBD versus a placebo for… Read More>> NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX About CBDWire CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge. To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.CBDWire.com Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer Do you have questions or are you interested in working with CNW? Ask Our Editor CBDWire (CBDW) Denver, Colorado www.CBDWire.com 303.498.7722 Office Editor@CBDWire.com CBDWire is part of the InvestorBrandNetwork.